The addition of daratumumab to bortezomib, melphalan, and prednisone (VMP) in patients with newly diagnosed multiple myeloma (NDMM) has for the first time been shown to have an overall survival benefit. Speaking at ASH 2019 Professor Maria-Victoria Mateos presented an update of the phase 3 ALCYONE study of more than 700 transplant-ineligible myeloma patients randomised ...
Daratumumab shows OS benefit in quadruplet therapy for NDMM
By Mardi Chapman
17 Dec 2019